Announcements
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
- Pharming Group to participate in May investor conference
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
- Pharming Group reports first quarter 2024 financial results and provides business update
- Pharming Group to report first quarter 2024 financial results on May 8
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
- Pharming Group announces the placement of €100 million convertible bonds due 2029
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 673.44m |
Free float | 657.75m |
P/E (TTM) | -- |
Market cap | 548.57m EUR |
EPS (TTM) | -0.016 EUR |
Data delayed at least 15 minutes.
More ▼